Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Michael, Milhollen"'
Autor:
Jennifer S. Carew, Allison Berger, Michael Thomas, Stephen Blakemore, Michael Milhollen, Sean A. Beausoleil, Anthony Possemato, Claudia M. Espitia, Peter G. Smith, Kevin R. Kelly, Steffan T. Nawrocki
PDF file - 1755K, Supplemental Figure 1: Effects of targeted p65 knockdown on cisplatin sensitivity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627036159925f122bbe6cee401c9efba
https://doi.org/10.1158/1078-0432.22451391
https://doi.org/10.1158/1078-0432.22451391
Autor:
Jennifer S. Carew, Allison Berger, Michael Thomas, Stephen Blakemore, Michael Milhollen, Sean A. Beausoleil, Anthony Possemato, Claudia M. Espitia, Peter G. Smith, Kevin R. Kelly, Steffan T. Nawrocki
PDF file - 71K, Supplemental Table 1. Proteins Altered >2-fold by Treatment with MLN4924.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f0b67ed86626b6eb94f1ada6e5c926e
https://doi.org/10.1158/1078-0432.22451385
https://doi.org/10.1158/1078-0432.22451385
Autor:
Jennifer S. Carew, Allison Berger, Michael Thomas, Stephen Blakemore, Michael Milhollen, Sean A. Beausoleil, Anthony Possemato, Claudia M. Espitia, Peter G. Smith, Kevin R. Kelly, Steffan T. Nawrocki
PDF file - 3554K, Supplemental Figure 2: Effects of caspase inhibition and antioxidant treatment on MLN4924/cisplatin-induced DNA damage.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a0198af11e49361783b5d136b4d01d
https://doi.org/10.1158/1078-0432.22451388
https://doi.org/10.1158/1078-0432.22451388
Autor:
Jennifer S. Carew, Allison Berger, Michael Thomas, Stephen Blakemore, Michael Milhollen, Sean A. Beausoleil, Anthony Possemato, Claudia M. Espitia, Peter G. Smith, Kevin R. Kelly, Steffan T. Nawrocki
Purpose: Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of treatment failure and novel therapeutic strategies are urgently needed. MLN4924 is a NEDDylation inhibitor currently u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cbb66a754615a2340af9aba36490809
https://doi.org/10.1158/1078-0432.c.6522186.v1
https://doi.org/10.1158/1078-0432.c.6522186.v1
Autor:
Keli Song, James Minissale, Richard A. Klinghoffer, James Garnsey, Katherine Galvin, Kristina Xega, Sai M Pulukuri, James M. Gavin, Xiaofeng Yang, Pooja Shah, Gary Shapiro, Cong Li, Vaishali Shinde, Eric S. Lightcap, Dennis Huszar, Zhen Lu, Stephen Grossman, Erik Koenig, Pengfei Yu, Steve Langston, Hisashi Imaichi, Serge Y. Fuchs, Mithun Khattar, Beryl A. Hatton, Yu Fu, Hongru Zhang, Dylan England, Michael Milhollen, Jessica Riceberg, Xingyue He
Publikováno v:
Sci Transl Med
SUMOylation, the covalent conjugation of small ubiquitin-like modifier (SUMO) proteins to protein substrates, has been reported to suppress type I interferon (IFN1) responses. TAK-981, a selective small molecule inhibitor of SUMOylation, pharmacologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4bd5030d5032a91542312ca00873097
https://doi.org/10.1126/scitranslmed.aba7791
https://doi.org/10.1126/scitranslmed.aba7791
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72230303f8aa4b6b6f446cbbbf8ed1b4
https://doi.org/10.1038/s41375-018-0167-0
https://doi.org/10.1038/s41375-018-0167-0
Autor:
Kristina Xega, Michael Milhollen, Dennis Huszar, Erik Koenig, Eric S. Lightcap, Vaishali Shinde, Stephen Grossman, Keli Song, Sharon Friedlander, Omid Ghasemi, Allison Berger, Pooja Shah, Gary Shapiro, Agatha Zawadzka
Publikováno v:
Cancer Research. 79:3079-3079
TAK-981 is a small molecule inhibitor of the SUMOylation enzyme cascade which is currently in a Phase I clinical trial (NCT03648372). TAK-981 selectively inhibits the activity of the SUMO activating enzyme, forming a covalent adduct between TAK-981 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beaf8c3a9691f41448b0b1092eaaf55b
https://doi.org/10.1158/1538-7445.am2019-3079
https://doi.org/10.1158/1538-7445.am2019-3079
Autor:
Anindya Dutta, Amir A. Jazaeri, Etsuko Shibata, Jonghoon Park, Michael Milhollen, Susan C. Modesitt, Allison Berger, Mark R. Conaway, Jennifer Bryant, Peter G. Smith
Publikováno v:
Molecular Cancer Therapeutics. 12:1958-1967
The nearly ubiquitous development of chemoresistant disease remains a major obstacle against improving outcomes for patients with ovarian cancer. In this investigation, we evaluated the preclinical activity of MLN4924, an investigational inhibitor of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa3385cc31febc1f0ccd5b28fd13a13
https://doi.org/10.1158/1535-7163.mct-12-1028
https://doi.org/10.1158/1535-7163.mct-12-1028
Autor:
Sean A. Beausoleil, Michael Milhollen, Stephen J. Blakemore, Anthony Possemato, Claudia M. Espitia, Pete Smith, Michael P. Thomas, Allison Berger, Steffan T. Nawrocki, Kevin R. Kelly, Jennifer S. Carew
Publikováno v:
Clinical Cancer Research. 19:3577-3590
Purpose: Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of treatment failure and novel therapeutic strategies are urgently needed. MLN4924 is a NEDDylation inhibitor currently u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9363a3310fcccdf12d82d74fb8959970
https://doi.org/10.1158/1078-0432.ccr-12-3212
https://doi.org/10.1158/1078-0432.ccr-12-3212
Autor:
John Newcomb, James M. Gavin, Nancy J. Bump, Stephen Tirrell, Lawrence R. Dick, Saurabh Menon, Jessica Huck, Petter Veiby, Benjamin S. Amidon, Yu Yang, Marc L. Hyer, Paul D. Greenspan, Fleming Paul E, Teresa A. Soucy, Jim Brownell, Michael Sintchak, Josh Powe, Steve Langston, Mark Manfredi, Judy Shi, Jeff Ciavarri, Darshan S. Sappal, Frank Bruzzese, Mike Kuranda, Katherine Galvin, Michael Milhollen, Ping Li, Neil F. Bence, Jing Tao Wu, Claudia Rabino, Chris Claiborne, Tary Traore, Jennifer Duffy, Jessica Riceberg, Robert J. Griffin, Kara Hoar, Anya Lublinsky, Bradley Stringer, Sai M Pulukuri
Publikováno v:
Nature medicine. 24(2)
The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis. The therapeutic potential of this pathway has been validated by the clinical successes of a number of UPS modulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2e77aca37457d7e649a61cfd0e086b
https://pubmed.ncbi.nlm.nih.gov/29334375
https://pubmed.ncbi.nlm.nih.gov/29334375